Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of D-Glutamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | GRM8 | O00222 | 2/20 | 0.72 |
| ▸ | GRM6 | O15303 | 2/20 | 0.72 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.72 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.72 |
| ▸ | GSR | P00390 | 2/20 | 0.72 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.72 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.72 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.72 |
| ▸ | GRM5 | P41594 | 1/20 | 0.72 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.72 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.72 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.72 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.72 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.72 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.72 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.72 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.72 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.72 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamic Acid SCHEMBL1963375 | 1.00 | CYP1A2 (0.72) | CYP1A2GRM8GRM6GRM7GRM4 | |
| D-Glutamate SCHEMBL9679290 | 1.00 | CYP1A2 (0.72) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL9679295 | 1.00 | CYP1A2 (0.72) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL1444866 | 0.94 | CYP1A2 (0.82) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL4531318 | 0.94 | CYP1A2 (0.82) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL29406755 | 0.94 | CYP1A2 (0.82) | CYP1A2GRM8GRM6GRM7GRM4 | |
| D-Glutamate SCHEMBL1444865 | 0.94 | CYP1A2 (0.82) | CYP1A2GRM8GRM6GRM7GRM4 | |
| D-Glutamate SCHEMBL8637356 | 0.94 | CYP1A2 (0.82) | CYP1A2GRM8GRM6GRM7GRM4 | |
| D-Glutamate SCHEMBL4531315 | 0.94 | CYP1A2 (0.82) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL8843182 | 0.93 | CYP1A2 (0.62) | CYP1A2GRM8GRM6GRM7GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148887-A1 | SITE SPECIFIC ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| US-11964024-B2 | B7H4-targeted antibody-drug conjugates and methods of use thereof | MERSANA THERAPEUTICS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4271713-A1 | B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Mersana Therapeutics, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116917323-A | Antibody-drug conjugates targeting B7H4 and methods of use thereof | 梅尔莎纳医疗公司 | 2023-10-20 | — | — | CN | disclosed |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230321048-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | MERSANA THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4218826-A2 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | Mersana Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230172910-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | MERSANA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| CN-116196435-A | Antibody drug conjugates comprising STING agonists | 梅尔莎纳医疗公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-115884793-A | Site-specific antibody-drug conjugates with peptide-containing linkers | 梅尔莎纳医疗公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-115768485-A | Antibody drug conjugates comprising STING agonists | 梅尔莎纳医疗公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4126065-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | Mersana Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220233707-A1 | B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. | 2022-07-28 | — | — | US | disclosed |
| WO-2022147532-A1 | B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2021202984-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | MERSANA THERAPEUTICS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20210220477-A1 | SITE SPECIFIC ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| WO-2011072264-A2 | METHODS AND COMPOSITIONS FOR BIOMASS TREATMENT | QTEROS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233707-A1 | B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | CD44, NECTIN4, HRH4 | CYP1A2 4027/4885GRM8 1068/4885GRM6 950/4885 |
| US-20230321048-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | STING1, CGAS, IFNAR1 | CYP1A2 3483/4885GRM8 2072/4885GRM6 2834/4885 |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | CD2BP2, DNPEP, LNPEP | CYP1A2 4653/4885GRM8 2047/4885GRM6 1869/4885 |
| US-20230172910-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | STING1, CGAS, IFNAR1 | CYP1A2 3483/4885GRM8 2072/4885GRM6 2834/4885 |
| US-11964024-B2 | B7H4-targeted antibody-drug conjugates and methods of use thereof | CD44, NECTIN4, HRH4 | CYP1A2 4027/4885GRM8 1068/4885GRM6 950/4885 |
| US-20210220477-A1 | SITE SPECIFIC ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | CD2BP2, DNPEP, LNPEP | CYP1A2 4653/4885GRM8 2047/4885GRM6 1869/4885 |
| US-20240148887-A1 | SITE SPECIFIC ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | CD2BP2, DNPEP, LNPEP | CYP1A2 4653/4885GRM8 2047/4885GRM6 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.